The pertinent move has everything to do with the GLP-1 revolution.<\/p>\n<\/p>\n
Eli Lilly, in particular, has ridden the weight-loss wave into a class of its own.<\/p>\n
For perspective, over the past few months, it briefly crossed the $1 trillion market cap<\/a> threshold, CNBC reported<\/a>, with Mr. Market going all-in on the ubiquitous obesity and diabetes industry reshaping global health care.<\/p>\n Over the past six months, Eli Lilly stock has rewarded investors handsomely, delivering a 58% gain<\/a>.<\/p>\n However, since I last covered Eli Lilly<\/a> on Dec. 20, 2025, it\u2019s down about 3%.<\/p>\n At the same time, Lilly has been delivering multibillion-dollar quarters, powered by surging demand for Mounjaro and Zepbound.<\/p>\n Moreover, market estimates peg the obesity drug market at $100 billion by 2030, with Lilly dominating it.<\/p>\n So clearly, JPMorgan\u2019s multibillion-dollar allocation aligns with what appears to be a major structural shift in medicine and consumer behavior.<\/p>\n Market value: $1.59 trillion (prior: $1.67 trillion)<\/p>\n Inflows (outflows) as percentage of total MV: 6.26%<\/p>\n New purchases: 638 stocks<\/p>\n Added to: 2,643 stocks<\/p>\n Sold out of: 605 stocks<\/p>\n Reduced holdings in: 3,425 stocks<\/p>\n Top 10 holdings concentration: 26.3%<\/p>\n Turnover: 15.6%<\/p>\n Turnover (alt): 5.5% The GLP-1 engine has been humming along exceptionally well, and Eli Lilly\u2019s results clearly reflect that.<\/p>\n In Q4 2025, Eli Lilly generated an eye-popping $19.3 billion in sales<\/a>, up 43% year over year, and posted $7.54 in adjusted EPS, beating expectations by a comfortable margin.<\/p>\n More Wall Street<\/a><\/p>\n Mounjaro brought in nearly $7.4 billion, while Zepbound added roughly $4.3 billion.<\/p>\n As we look ahead, things are only going to get more lucrative, with Lilly guiding to $80 billion to $83 billion in sales<\/a> and $33.50 to $35.00 in EPS, leaning heavily on the relentless demand for obesity and diabetes treatments.<\/p>\n Goldman Sachs expects<\/a> the global anti-obesity drug market to jump to roughly $95 billion by 2030, spearheaded by GLP-1 therapies.<\/p>\n JPMorgan forecasts<\/a> the broader GLP-1 market to rise to $100 billion by 2030, split between diabetes and obesity demand.<\/p>\n Morgan Stanley projects<\/a> that the obesity-drug market could reach nearly $150 billion by 2035.<\/p>\n Story Continues <\/p>\n Market share gains reinforce the story.<\/p>\n Zepbound overtook Novo Nordisk\u2019s Wegovy in U.S. prescriptions at multiple points last year, according to Reuters<\/a>, and some sector snapshots showed Eli Lilly holding more than half of the U.S. obesity-drug market in 2025, BioPharma Dive<\/a> reported.<\/p>\n For perspective, that incredible lead is far from accidental.<\/p>\n Head-to-head trial data<\/a> from SURMOUNT-5 showed that tirzepatide (Eli Lilly\u2019s dual-action GLP-1 drug) posted superior weight loss when pitted against semaglutide at 72 weeks.<\/p>\n Lilly also benefits immensely from brand equity.<\/p>\n Mounjaro dominates the lucrative diabetes market, while Zepbound anchors the obesity space, and prescribers have become a lot more comfortable with a specific molecule across both lanes.<\/p>\n State Street SPDR S&P 500<\/a> (put): $7.10 billion<\/p>\n JPMorgan BetaBuilder: $4.14 billion<\/p>\n iShares U.S. Treasury: $3.53 billion<\/p>\n Eli Lilly: $2.93 billion<\/p>\n Amphenol: $2.35 billion Meta Platforms: 0.59%<\/p>\n Vanguard S&P 500 ETF: 0.54%<\/p>\n Microsoft: 0.44%<\/p>\n iShares Core S&P 500: 0.41%<\/p>\n Oracle: 0.33% Outside of Eli Lilly, JPMorgan\u2019s 13F essentially reads like a robust portfolio that\u2019s tailor-made for both offense and defense.<\/p>\n Perhaps the biggest headline is the bank\u2019s massive $7.1 billion put option on the S&P 500 (SPY<\/a>), WhaleWisdom<\/a> noted.<\/p>\n As the index hovers near record highs, it feels more like an institutional-scale insurance, protecting against a broad market drawdown. With a $1.59 trillion equity book, risk management becomes imperative.<\/p>\n On the growth side, JPMorgan added $4.14 billion to its BetaBuilders ETF lineup, leaning heavily on broad stock-market exposure through low-cost index vehicles. Additionally, it allocated $3.53 billion into a U.S. Treasury ETF, locking in attractive yields while ensuring flexibility.<\/p>\n On the tech side, JPMorgan bet big on Amphenol, adding $2.35 billion to its stake in the popular connector and sensor maker.<\/p>\n Amphenol has been a highly rewarding \u201cpicks and shovels\u201d player in AI<\/a> data centers, fiber, and high-speed connectivity.<\/p>\n The company has posted eye-catching 40% organic revenue growth in recent quarters, reported Investing.com<\/a>, driven by strong demand for AI infrastructure, and has seen a tremendous 71% stock market gain over the past nine months.<\/p>\n Meanwhile, trims in Meta, Microsoft, and Oracle mostly look like profit-taking, not retreat. Nvidia, Microsoft, Apple, Amazon, and Broadcom still account for nearly 18% of the portfolio.<\/p>\n Related: Goldman Sachs delivers contrarian take on the economy<\/a><\/p>\n This story was originally published by TheStreet<\/a> on Feb 16, 2026, where it first appeared in the Investing<\/a> section. Add TheStreet as a Preferred Source by clicking here.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"JPMorgan Chase just planted a massive $2.93 billion flag in perhaps one of the hottest corners of the…\n","protected":false},"author":2,"featured_media":479653,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[49,48,194185,9949,84,392,21985,194186,121],"class_list":{"0":"post-479652","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-ca","9":"tag-canada","10":"tag-drug-market","11":"tag-eli-lilly","12":"tag-health","13":"tag-healthcare","14":"tag-jpmorgan-chase","15":"tag-obesity-and-diabetes","16":"tag-stock-market"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/479652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=479652"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/479652\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/479653"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=479652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=479652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=479652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"JPMorgan](\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2026\/02\/531e3736fa96adcadf7de6b15a57919d.jpeg\")
JPMorgan disclosed a $2.93 billion stake in Eli Lilly in its latest 13F filing.Photo by Bloomberg on Getty Images \u00b7 Photo by Bloomberg on Getty Images <\/p>\n
Source: WhaleWisdom<\/p>\n
Source: WhaleWisdom<\/p>\n
Source: WhaleWisdom<\/p>\n